慢性閉塞性肺疾患治療の世界市場

◆英語タイトル:Chronic Obstructive Pulmonary Disease Treatment Market (Drug Class: Combination, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, and Others; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 -2026
◆商品コード:TPM-C03097
◆発行会社(リサーチ会社):Transparency Market Research
◆発行日:2019年2月
◆ページ数:184
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,795 ⇒換算¥637,450見積依頼/購入/質問フォーム
Multi UserUSD8,795 ⇒換算¥967,450見積依頼/購入/質問フォーム
Global Site LicenseUSD11,795 ⇒換算¥1,297,450見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTransparency Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Transparency Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Transparency Market Researchが調査・発行した当レポートは、慢性閉塞性肺疾患治療の世界市場について調べ、慢性閉塞性肺疾患治療の世界規模、市場動向、市場環境、薬剤クラス別(併用剤、気管支拡張剤、コルチコステロイド、ホスホジエステラーゼ4阻害剤、ムコキネティクス、その他)分析、流通経路別(院内薬局、小売薬局、オンライン薬局)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめました。
・序文・調査範囲・調査手法
・エグゼクティブサマリー
・慢性閉塞性肺疾患治療の世界市場動向
・慢性閉塞性肺疾患治療の世界市場環境
・慢性閉塞性肺疾患治療の世界市場規模
・慢性閉塞性肺疾患治療の世界市場規模:薬剤クラス別(併用剤、気管支拡張剤、コルチコステロイド、ホスホジエステラーゼ4阻害剤、ムコキネティクス、その他)
・慢性閉塞性肺疾患治療の世界市場規模:流通経路別(院内薬局、小売薬局、オンライン薬局)
・慢性閉塞性肺疾患治療の世界市場:地域別市場規模・分析
・慢性閉塞性肺疾患治療の北米市場規模・予測
・慢性閉塞性肺疾患治療のアメリカ市場規模・予測
・慢性閉塞性肺疾患治療の中南米市場規模・予測
・慢性閉塞性肺疾患治療のヨーロッパ市場規模・予測
・慢性閉塞性肺疾患治療のアジア市場規模・予測
・慢性閉塞性肺疾患治療の日本市場規模・予測
・慢性閉塞性肺疾患治療の中国市場規模・予測
・慢性閉塞性肺疾患治療のインド市場規模・予測
・慢性閉塞性肺疾患治療の中東市場規模・予測
・慢性閉塞性肺疾患治療のアフリカ市場規模・予測
・競争状況・関連企業情報
【レポートの概要】

Global Chronic Obstructive Pulmonary Disease Treatment Market: Overview

This report analyzes the current and future scenario of the global chronic obstructive pulmonary disease (COPD) treatment market. Rise in prevalence of COPD, increase in the adoption of combination therapy, and surge in awareness about COPD treatment are the key factors anticipated to drive the global market. Additionally, increase in the geriatric population, rise in importance of COPD management, and surge in the number of respiratory care centers contribute to the growth of the global market. According to the Global Initiative for Asthma (GINA) 2018, COPD is the third leading cause of death in the U.S., with large portion of population being undiagnosed.

The global chronic obstructive pulmonary disease treatment market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drug class, distribution channel, and region. A detailed qualitative analysis of drivers and restraints of the market, and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global chronic obstructive pulmonary disease treatment market.

New drug development by market players through collaborations and increase in research and development expenditure are anticipated to drive the global market. In February 2016, Propeller Health and Novartis Pharma AG entered into collaboration to develop a custom add-on sensor for the Breezhaler inhaler, a device indicated for COPD treatments. This collaboration aims to connect these medications to Propeller’s digital health platform..

Global Chronic Obstructive Pulmonary Disease Treatment Market: Key Segments

In terms of drug class, the global chronic obstructive pulmonary disease treatment market has been segmented into combination, bronchodilators, corticosteroids, phosphodiesterase type 4 inhibitors, mucokineticsm and others. The combination segment has been divided into long acting muscarinic antagonist & inhaled corticosteroids (LAMA-ICS), long acting beta agonist & inhaled corticosteroids (LABA-ICS), triple therapy, and others. The bronchodilators segment has been classified into long acting beta agonist (LABA), short acting beta agonist (SABA), and long acting muscarinic antagonist (LAMA). Based on distribution channel, the market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment is projected to expand at the fastest CAGR due to increase in the number of patients preferring retail pharmacies. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Chronic Obstructive Pulmonary Disease Treatment Market: Regional Outlook

In terms of region, the global chronic obstructive pulmonary disease treatment market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the global chronic obstructive pulmonary disease treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Key players profiled in the market report include AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline plc, Novartis AG, CHIESI Farmaceutici S.p.A., Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd), Teva Pharmaceutical Industries Ltd, Mylan N.V., and Orion Corporation.
The global chronic obstructive pulmonary disease treatment market has been segmented as below:

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Drug Class
Combination
Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
Triple Therapy
Others
Bronchodilators
Long Acting Beta Agonist (LABA)
Short Acting Beta Agonist (SABA)
Long Acting Muscarinic Antagonist (LAMA)
Corticosteroids
Phosphodiesterase Type 4 Inhibitors
Mucokinetics
Others

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Region
North America
U.S.
Canada
Europe
Germany
U.K.
Italy
France
Spain
Rest of Europe
Asia Pacific
India
China
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Israel
Rest of Middle East & Africa

【レポートの目次】

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global COPD Treatment Market

4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global COPD Treatment Market Analysis and Forecast, 2016–2026

5. Key Insights
5.1. Innovative Solutions for COPD Treatment
5.2. Pipeline Analysis

6. Global COPD Treatment Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2016–2026
6.3.1. Combination
6.3.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
6.3.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
6.3.1.3. Triple Therapy
6.3.1.4. Others
6.3.2. Corticosteroids
6.3.3. Bronchodilators
6.3.3.1. Long Acting Beta Agonist (LABA)
6.3.3.2. Short Acting Beta Agonist (SABA)
6.3.3.3. Long Acting Muscarinic Antagonist (LAMA)
6.3.4. Phosphodiesterase Type 4 Inhibitors
6.3.5. Mucokinetics
6.3.6. Others
6.4. Market Attractiveness, by Drug Class

7. Global COPD Treatment Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Distribution Channel, 2016–2026
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Market Attractiveness, by Distribution Channel

8. Global COPD Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness By Region

9. North America COPD Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug Class, 2016–2026
9.2.1. Combination
9.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
9.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
9.2.1.3. Triple Therapy
9.2.1.4. Others
9.2.2. Corticosteroids
9.2.3. Bronchodilators
9.2.3.1. Long Acting Beta Agonist (LABA)
9.2.3.2. Short Acting Beta Agonist (SABA)
9.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
9.2.4. Phosphodiesterase Type 4 Inhibitors
9.2.5. Mucokinetics
9.2.6. Others
9.3. Market Value Forecast, by Distribution Channel, 2016–2026
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Value Forecast, by Country, 2016–2026
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country

10. Europe COPD Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2016–2026
10.2.1. Combination
10.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
10.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
10.2.1.3. Triple Therapy
10.2.1.4. Others
10.2.2. Corticosteroids
10.2.3. Bronchodilators
10.2.3.1. Long Acting Beta Agonist (LABA)
10.2.3.2. Short Acting Beta Agonist (SABA)
10.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
10.2.4. Phosphodiesterase Type 4 Inhibitors
10.2.5. Mucokinetics
10.2.6. Others
10.3. Market Value Forecast, by Distribution Channel, 2016–2026
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Value Forecast, by Country/Sub-region, 2016–2026
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region

11. Asia Pacific COPD Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2016–2026
11.2.1. Combination
11.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
11.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
11.2.1.3. Triple Therapy
11.2.1.4. Others
11.2.2. Corticosteroids
11.2.3. Bronchodilators
11.2.3.1. Long Acting Beta Agonist (LABA)
11.2.3.2. Short Acting Beta Agonist (SABA)
11.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
11.2.4. Phosphodiesterase Type 4 Inhibitors
11.2.5. Mucokinetics
11.2.6. Others
11.3. Market Value Forecast, by Distribution Channel, 2016–2026
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Market Value Forecast, by Country/Sub-region, 2016–2026
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region

12. Latin America COPD Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2016–2026
12.2.1. Combination
12.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
12.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
12.2.1.3. Triple Therapy
12.2.1.4. Others
12.2.2. Corticosteroids
12.2.3. Bronchodilators
12.2.3.1. Long Acting Beta Agonist (LABA)
12.2.3.2. Short Acting Beta Agonist (SABA)
12.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
12.2.4. Phosphodiesterase Type 4 Inhibitors
12.2.5. Mucokinetics
12.2.6. Others
12.3. Market Value Forecast, by Distribution Channel, 2016–2026
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Market Value Forecast, by Country/Sub-region, 2016–2026
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region

13. Middle East & Africa COPD Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2016–2026
13.2.1. Combination
13.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
13.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
13.2.1.3. Triple Therapy
13.2.1.4. Others
13.2.2. Corticosteroids
13.2.3. Bronchodilators
13.2.3.1. Long Acting Beta Agonist (LABA)
13.2.3.2. Short Acting Beta Agonist (SABA)
13.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
13.2.4. Phosphodiesterase Type 4 Inhibitors
13.2.5. Mucokinetics
13.2.6. Others
13.3. Market Value Forecast, by Distribution Channel, 2016–2026
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Market Value Forecast, by Country/Sub-region, 2016–2026
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region

14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis, by Company, 2017
14.3. Company Profiles
14.3.1. AstraZeneca
14.3.2. Boehringer Ingelheim Pharmaceuticals, Inc.
14.3.3. GlaxoSmithKline plc
14.3.4. Novartis AG
14.3.5. Teva Pharmaceutical Industries Ltd.
14.3.6. Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd.)
14.3.7. CHIESI Farmaceutici S.p.A.
14.3.8. Orion Corporation
14.3.9. Mylan N.V.

List of Tables

Table 01 Pipeline Analysis
Table 02 Pipeline Analysis
Table 03 Pipeline Analysis
Table 04 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 05 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Combination Therapy, 2016–2026
Table 06 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Bronchodilators, 2016–2026
Table 07 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 08 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Region, 2016–2026
Table 09 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 10 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Combination Therapy, 2016–2026
Table 11 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Bronchodilators, 2016–2026
Table 12 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 13 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Country, 2016–2026
Table 14 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 15 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Combination Therapy, 2016–2026
Table 16 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Bronchodilators, 2016–2026
Table 17 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 18 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 19 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 20 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Combination Therapy, 2016–2026
Table 21 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Bronchodilators, 2016–2026
Table 22 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 23 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 24 Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 25 Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Combination Therapy, 2016–2026
Table 26 Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Bronchodilators, 2016–2026
Table 27 Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 28 Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 29 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 30 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Combination Therapy, 2016–2026
Table 31 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Bronchodilators, 2016–2026
Table 32 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 33 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026

List of Figures

Figure 01 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) and Distribution, by Region, 2017 and 2026
Figure 02 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn), by Drug Class, 2017
Figure 03 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 04 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 05 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Combination, 2016–2026
Figure 06 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Bronchodilators, 2016–2026
Figure 07 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Corticosteroids, 2016–2026
Figure 08 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Phosphodiesterase Type 4 Inhibitors, 2016–2026
Figure 09 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Mucokinetics, 2016–2026
Figure 10 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Others, 2016–2026
Figure 11 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
Figure 12 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 13 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospital Pharmacies, 2016–2026
Figure 14 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Independent Pharmacies, 2016–2026
Figure 15 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacies, 2016–2026
Figure 16 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 17 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Region, 2017 and 2026
Figure 18 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Region, 2018–2026
Figure 19 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 20 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 21 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
Figure 22 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 23 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2018 - 2026
Figure 24 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country, 2017 and 2026
Figure 25 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country, 2018–2026
Figure 26 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 27 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 28 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
Figure 29 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 30 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2018 - 2026
Figure 31 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 32 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 33 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 34 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 35 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
Figure 36 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 37 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 38 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 39 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 40 Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 41 Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 42 Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
Figure 43 Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 44 Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 45 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 46 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 47 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
Figure 48 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 49 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 50 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 51 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 52 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share, by Company, 2017
Figure 53 AstraZeneca Respiratory Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 54 AstraZeneca R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 55 AstraZeneca Breakdown of Net Sales (%), by Region, 2017
Figure 56 AstraZeneca Breakdown of Net Sales (%), by Product Segment, 2017
Figure 57 Boehringer Ingelheim International GmbH , Human Pharmaceuticals Business Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 58 Boehringer Ingelheim International GmbH R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 59 Boehringer Ingelheim International GmbH Breakdown of Net Sales (%), by Region, 2017
Figure 60 Boehringer Ingelheim International GmbH Breakdown of Net Sales (%), by Business Segment, 2017
Figure 61 GlaxoSmithKline plc Respiratory Business Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 62 GlaxoSmithKline plc R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 63 GlaxoSmithKline plc Breakdown of Net Sales (%), by Region, 2017
Figure 64 GlaxoSmithKline plc Breakdown of Net Sales (%), by Business Segment, 2017
Figure 65 Novartis AG COPD Portfolio Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 66 Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 67 Novartis AG Breakdown of Net Sales (%), by Country, 2017
Figure 68 Novartis AG Breakdown of Net Sales (%), by Business Segment, 2017
Figure 69 Teva Pharmaceutical Industries Ltd Respiratory Medicine Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 70 Teva Pharmaceutical Industries Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 71 Teva Pharmaceutical Industries Ltd Breakdown of Net Sales (%), by Region, 2017
Figure 72 Teva Pharmaceutical Industries Ltd Breakdown of Net Sales (%), by Business Segment, 2017
Figure 73 Sumitomo Dainippon Pharma Co., Ltd Pharmaceuticals Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 74 Sumitomo Dainippon Pharma Co., Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 75 Sumitomo Dainippon Pharma Co., Ltd Breakdown of Net Sales (%), by Region, 2017
Figure 76 Sumitomo Dainippon Pharma Co., Ltd Breakdown of Net Sales (%), by Product Segment, 2017
Figure 77 CHIESI Farmaceutici S.p.A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 78 CHIESI Farmaceutici S.p.A. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 79 CHIESI Farmaceutici S.p.A. Breakdown of Net Sales (%), by Region, 2017
Figure 80 CHIESI Farmaceutici S.p.A. Breakdown of Net Sales (%), by Therapeutics Area, 2017
Figure 81 Orion Corporation Pharmaceuticals Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 82 Orion Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 83 Orion Corporation Breakdown of Net Sales (%), by Country, 2017
Figure 84 Orion Corporation Breakdown of Net Sales (%), by Business Segment, 2017
Figure 85 Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 86 Mylan N.V. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 87 Mylan N.V. Breakdown of Net Sales (%), by Region, 2017

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[慢性閉塞性肺疾患治療の世界市場]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆